MediWound CEO Gonen exercises warrants for 8,168 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MediWound Ltd. Chief Executive Officer Ofer Gonen exercised 8,168 Series A Warrants at an exercise price of $13.475 per share to acquire 8,168 ordinary shares, paying the aggregate exercise price in cash; he did not sell the acquired shares. The filing also lists directly held options to buy ordinary shares, including 85,714 shares at $13.1425, expiring June 7, 2032, and 71,000 shares at $17.60, expiring March 4, 2036.
Insider Trade Summary
8,168 shares exercised/converted
Exercise
2 txns
Insider
Gonen Ofer
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Series A Warrants F1 | 8,168 | -- | -- |
| In-the-Money Exercise | Ordinary Shares F1 | 8,168 | $13.475 | $110K |
| Holding | Stock Option (right to buy ordinary shares) F5, F6 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F5, F7 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F5, F8 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F5, F9 | -- | -- | -- |
| Holding | Stock Option (right to buy ordinary shares) F5, F10 | -- | -- | -- |
| Holding | Ordinary Shares F2, F5 | -- | -- | -- |
| Holding | Ordinary Shares F3, F5 | -- | -- | -- |
| Holding | Ordinary Shares F4, F5 | -- | -- | -- |
Holdings After Transaction:
Series A Warrants — 0 warrants (Direct);
Ordinary Shares — 95,203 shares (Direct);
Stock Option (right to buy ordinary shares) — 404,987 options (Direct)
Footnotes (10)
- F1. On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 8,168 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I. The amount reported in Column 5 also includes 35,714 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and became fully vested on June 7, 2026.
- F2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F4. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vest upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F5. There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F6. The options reported in this row were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F7. The options reported in this row were granted to the Reporting Person on May 31, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F8. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F9. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
- F10. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vest upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
Key Figures
Series A Warrants exercised: 8,168 warrants
Exercise price: $13.475 per share
Ordinary shares acquired: 8,168 shares
+5 more
8 metrics
Series A Warrants exercised
8,168 warrants
Exercise reported by Ofer Gonen
Exercise price
$13.475 per share
Series A Warrants
Ordinary shares acquired
8,168 shares
Acquired upon warrant exercise
Underlying ordinary shares
85,714 shares
Stock options at $13.1425, expiring June 7, 2032
Underlying ordinary shares
86,000 shares
Stock options at $11.885, expiring May 31, 2033
Underlying ordinary shares
94,273 shares
Stock options at $12.729, expiring February 26, 2034
Underlying ordinary shares
68,000 shares
Stock options at $18.54, expiring February 11, 2035
Underlying ordinary shares
71,000 shares
Stock options at $17.60, expiring March 4, 2036
Key Terms
Series A Warrants, exercise price, restricted share units ("RSUs"), fully vested, +1 more
5 terms
Series A Warrants financial
"exercised Series A Warrants to purchase 8,168 ordinary shares"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
exercise price financial
"at an exercise price of $13.475 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"became fully vested on June 7, 2026"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did MDWD CEO Ofer Gonen report?
The reported positions were options for 85,714 shares at $13.1425, expiring June 7, 2032; 86,000 at $11.885, expiring May 31, 2033; 94,273 at $12.729, expiring February 26, 2034; 68,000 at $18.54, expiring February 11, 2035; and 71,000 at $17.60, expiring March 4, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
